Process Simulation Media Fills

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

1 Introduction to Safety Management April Objective The objective of this presentation is to highlight some of the basic elements of Safety Management.
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
Sterile Drug Process Inspections
GMP Document and Record Retention
Media Fill Protocol Luisa Stoppa
Batch Reworking and Reprocessing
Food Safety and Inspection Service Pathogen Reduction/HACCP.
Basic Principles of GMP
Principles of Information Systems, Seventh Edition2 An organization’s TPS must support the routine, day-to- day activities that occur in the normal course.
Chapter 11 Quality Control.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Reference, Retention and Reserve Samples
Microbiology and Serology
Dimensions of Data Quality M&E Capacity Strengthening Workshop, Addis Ababa 4 to 8 June 2012 Arif Rashid, TOPS.
Validation SAPRAA March 2013.
1 MEASURING THE EFFECTIVENESS OF THE NATION’S FOODSERVICE AND RETAIL FOOD PROTECTION SYSTEM.
World Health Organization
Multi-Agency Radiological Laboratory Analytical Protocols Manual: MARLAP Presentation to the Radiation Advisory Committee/Science Advisory Board April.
WHO Supplementary Training Modules GMP
Good Hygiene Practices Incoming Material Requirements Section 2 - Sub-Module 5.2.
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
Module 5 | Slide 1 of 22 January 2006 Sections 5 and 6 Basic Principles of GMP Complaints and Recalls.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Radiopharmaceutical Production
EQUIPMENT QUALIFICATION/VALIDATION
Codex Guidelines for the Application of HACCP
© 2009 Michigan State University licensed under CC-BY-SA, original at Corrective Action.
Advisory Committee for Pharmaceutical Science Sterilization Options Sterilization Options Kristen D. Evans Investigative Engineer, USFDA October 22, 2002.
VALIDATION METHODOLOGY
Module 5Slide 1 of 24 WHO - EDM Part One, Sections 6 and 7 Basic Principles of GMP Complaints and Recalls.
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Module 5 | Slide 1 of Sections 5 and 6 Basic Principles of GMP Complaints and Recalls.
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
Validation of Integrated line by Media Fill Test
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
Important informations
Hazards Identification and Risk Assessment
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Training Workshop: Training of BE Assessors Kiev, October 2009 Frequent Deficiencies Dr. Henrike Potthast Training workshop: Training.
Moderated By Eyal Rivlin Lev Hakongressim, Weizmann Science Park, Ness Ziona May 2008.
Statistical Quality Control/Statistical Process Control
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Validation | Slide 1 of 27 August 2006 Validation Supplementary Training Modules on Good Manufacturing Practice WHO Technical Report Series, No. 937, 2006.
McGraw-Hill/Irwin © The McGraw-Hill Companies 2010 Auditing Internal Control over Financial Reporting Chapter Seven.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Basic Principles of GMP
FDA Preliminary Concept Paper Sterile Drug Products Produced by Aseptic Processing This presentation summarizes the content of PDA’s official position,
Radiopharmaceutical Production
Module 12 - part 2Slide 1 of 23 WHO - EDM Basic Principles of GMP Documentation Part 2 Part One, 14.
USDA Public Meeting; Control of E. coli O157:H7
Environmental Control and Developing a Science-based Monitoring Program Richard L. Friedman, M.S. FDA/CDER.
Quality Control significance in pharmaceutical industry
In the name of God. Common Technical Document On Biotech.
World Health Organization
Quality Control and Assurance
FDA Guide To Aseptic Processing
Statistical Process Control
Food Production Systems
Chapter 10 Verification and Validation of Simulation Models
Design Controls and Production & Process Controls
Chapter 11 Quality Control.
Internal Control Internal control is the process designed and affected by owners, management, and other personnel. It is implemented to address business.
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

Process Simulation Media Fills Risk-Based Approach Process Simulation Media Fills 10/22/02 OPS Advisory Committee/ Aseptic Processing/ Media Fill/ BUratani

Process Simulation: Media Fill Objective of media fill to evaluate the capability of the aseptic process to produce sterile drug product Use of risk-based approach in media fill design incorporate the same risk factors for contamination that occur in production runs incorporate the worst case conditions that can occur in the operation: the process the manufacturing environment, and the operators

Critical Factors Study Design - Accuracy of Simulation simulate actual process as closely as possible, and address worst-case conditions Critical risk factors for contamination duration and size of run line speed: filling speeds manual manipulations personnel (number, shift changes, fatigue) routine and non-routine interventions

Size and Duration of Media Fill Run Size: number of units filled should be sufficient to reflect the effect of potential operator fatigue, and adequately represent the maximum number of interventions. Duration: long enough to challenge or stress the process, the environment, and the operators Stresses full duration media fills for manually intensive processes

Manual Manipulation start-up manipulations: weight checks, aseptic assembly of equipment aseptic sample collections aseptic additions (e.g., charging containers and closures, addition of sterile ingredients) interventions (routine and non-routine) operator fatigue

Personnel Number of personnel and their activities shift changes and breaks

Media Fill Assessment Concept paper provides guidance for: Criteria for removal of media fill units: The interventions in media fill should simulate what occurs in a commercial production run. Where units can be removed as part of an intervention, SOPs should include sufficient detail with respect to type of intervention and number of units removed Media fill records should document all interventions performed and the number of units removed. Unit accountability and reconciliation: integral and non-integral units. Incubation of all integral units.

Back up slides

Criteria for removal of intervention units The interventions in media fill should simulate what occurs in a commercial production run. Where units can be removed as part of an intervention, SOPs should include sufficient detail with respect to type of intervention and number of units removed Media fill records should document all interventions performed and the number of units removed.

Media Fill Assessment Mathematics/ statistical approach acceptance limit of < 0.1% contaminated units at 95% confidence level (approx. 1 in 5000). It is therefore important that every unit should be accounted for. FDA agrees with PDA that the target should be zero contaminated units regardless of size of run. Intermittent incidents of low contamination (e.g., 1:10,000) can be indicative of persistent problem and need for requalification.

Unit Accountability and Reconciliation Unit reconciliation, e.g. # units filled = # units incubated + # units rejected for cause + # units for growth promotion Accountability for all units removed during manual interventions at final inspection, non-integral units with container-closure defects All integral units (including units with cosmetic defects) should be incubated and counted as part of media fill evaluation

Unit Inspection (container/closure defects) Pre-incubation inspection: When a firm performs a final production inspection of units immediately after the media fill run, only those units found to be defective in container/closure integrity can be removed. Units with cosmetic defects should be incubated and included as part of the media fill run. Post-incubation inspection: Units found to be damaged after the pre-incubation inspection should be included as part of the media fill batch because such units would also likely to have escaped detection during normal production and be released to the market.

Acceptance Criteria All units should be fully accounted for and reconciled: All integral units should be incubated and counted as part of media fill assessment. Intervention units can be removed and not included as part of the media fill assessment if they met the predetermined criteria (specified in the SOP) as to the type of intervention and # of units removed. Non-integral units (container/closure defects) can be removed. All removed units (intervention and c-c defects) must be documented in media fill batch record.

Media and incubation temp Temperature and media chosen should bases on its ability to recover microorganism normally found environmentally or in the product bioburden. Temp: 20-35oC 2 temp: 20-25oC for 7 days, followed by 35C for 7 days 1 temp: 20- 25oC for 14 days media: TSB aerobic organisms, FTM for anaerobic organisms